Revised SPC: Ropilynz XL (ropinirole) 8 mg Prolonged-release Tablets

SPC updated with information on dopamine agonist withdrawal syndrome, which has been reported with dopamine agonists, including ropinirole. Limited data suggests those with impulse control disorders and those receiving high daily and/or cumulative doses may be at higher risk.

Source:

electronic Medicines compendium